Barostim device for heart failure treatment
Part of Heart & circulation clinical trials.
This trial tests a device called Barostim, which is implanted under the skin to stimulate nerves that help control heart failure. It's for people with mild to moderate heart failure whose symptoms are not fully controlled by medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have heart failure with symptoms that make you short of breath with activity (NYHA Class II or III) and your heart's pumping ability (ejection fraction) is less than 50%.
- You either have high levels of heart failure markers (NT-proBNP or BNP) in your blood, or you've had a worsening heart failure event in the last 6 months.
- You are on stable doses of recommended heart failure medications for at least 4 weeks.
- You can walk between 100 and 450 meters (about 1 to 4 football fields) in 6 minutes.
- You do not have advanced heart failure, severe kidney disease, or other conditions that would make the procedure unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a device called Barostim NEO that is implanted in the neck to help treat heart failure. It may improve symptoms by stimulating nerves that help the heart work better.
This study tests whether using two implanted devices (CardioMems and BaroStim) can improve heart function and symptoms in people with advanced heart failure. It aims to help patients who are already on standard medications get even better results.
This trial tests a device that treats and monitors heart failure. It may help people with chronic heart failure and reduced heart function who still have symptoms despite standard treatments.
This study tests a remote monitoring device that sends information to your care team to help adjust your heart failure medications. It aims to improve your condition after a hospital stay for heart failure.
This study tests whether a CardioPulmonary Management (CPM) system device used at home is safe and can improve outcomes for people with chronic heart failure. It may help manage symptoms and reduce complications, especially for higher-risk patients.
This study tests whether a heart-related device called CCM can improve symptoms and daily function in people with heart failure and a moderately reduced pumping strength. It may help if you’ve had recent heart-failure-related hospital care or urgent treatment and your heart and overall health fit the study limits.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.